

PRESS RELEASE
October 30, 2019

Nomination Committee appointed for the 2020 Annual General Meeting in SyntheticMR

The Chairman of SyntheticMR AB has established a Nomination Committee for the Annual General Meeting, which is planned to be held on May 5th, 2020. The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights, that have accepted the invitation to participate in the committee.

The following shareholders have been identified as the three largest shareholders as of 2019-09-30 who are willing to be part of the Nomination Committee and they have appointed the following members:

Nortal Investments AB: Staffan Persson
Handelsbanken Fonder: Suzanne Sandler
Marcel Warntjes: Magnus Ingmarsson

In total, the Nomination Committee represents approx. 47 percent of the total number of shares and votes in the company. All representatives are independent in relation to the company and its executive management. Suzanne Sandler och Magnus Ingmarsson are also independent in relation to Nortal Investments AB, which is the largest shareholder in the company in terms of votes.

The Committee's assignment is to present to the Annual General Meeting proposals regarding Chairman and other members of the board as well as remuneration to the Board's members. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2021.

Shareholders who wish to submit proposals to the Nomination Committee can do so by email to chairman of the board: johan.sedih@btinternet.com

For further information, please contact chairman of the board Johan Sedih,
johan.sedih@btinternet.com, tel + 44 7920 154333

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB product SyMRI® delivers multiple contrast images and quantitative data from a single 6-minute scan – to improve patient throughput and objective decision support for clinicians. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock Market in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com.